Breast Cancer Research Review Issue 81
In this issue:
HypoG-01: 3- vs. 5-week radiotherapy in early breast cancer
DESTINY-Breast-05: T-DXd vs. T-DM1 in residual HER2+ early breast cancer
J-START: incidence of advanced breast cancer with ultrasound + mammography
European trends in breast cancer incidence/mortality 1978–2019
TRAIN-3: a shortened neoadjuvant chemotherapy regimen guided by MRI
RxPONDER: cognitive impairment with endocrine therapy vs. chemotherapy + endocrine therapy
Fulvestrant + abemaciclib vs. imlunestrant + abemaciclib in HR+/HER2– breast cancer
Real-world outcomes in HR+/HER2− breast cancer after progression with endocrine therapy + CDK4/6 inhibitors
Neoadjuvant endocrine therapy + CDK4/6 inhibition vs. chemotherapy in HR+ breast cancer
CARABELA: neoadjuvant chemotherapy vs. abemaciclib + letrozole in HR+/HER2− highly proliferative breast cancer
Expert contributor
Dr Hilary Martin
Dr Hilary Martin, is a medical oncologist at Fiona Stanley Hospital Perth subspecialising in breast cancer. Her initial oncology training was undertaken in South Australia. She subsequently worked as a breast unit fellow at the Royal Marsden Hospital, London, and also as a clinical fellow at Royal Perth Hospital. She has a Masters of Public […]
Latest Publications and Videos
Stay up to date with our latest clinical information.
Explore Research Review Publications and Videos
Dive into our publications and videos content from over 50 areas of medicine including Cardiology, Diabetes, Oncology, Haematology and Psychiatry.
Terms and Conditions
Website terms of use
By using our website, you agree to follow these terms and conditions.
Privacy policy
We take your privacy seriously. To understand how we collect, use, and protect your information, please read our Privacy Policy, which is part of these terms.
Copyright and use of website content
The content of our website is protected by copyright, trademarks, and other legal rights. You can: view, download, or print a single copy of content for your personal or professional use.
You cannot: copy, modify, or distribute website content, or use our website content for commercial purposes or in other works without permission.
Links to third-party websites
The Research Review website may link to third-party websites for your convenience. However:
We do not endorse or approve their products, services, or actions.
We are not responsible for their content or how they operate.
There is no formal partnership between us and third parties unless we clearly state otherwise.
Disclaimer and limitation of liability
We do our best to keep the information on our website accurate, but we do not guarantee that it is always correct or up to date.
To the fullest extent allowed by law, we are not responsible for:
Any loss, damage, or costs you may suffer from using (or being unable to use) our website.
Any decisions you make based on the information provided.
Any business losses, such as lost profits, lost data, or business interruptions.
Governing law
These terms are governed by New Zealand law. If there is a dispute, it must be resolved in a New Zealand court.